MedTrace Logo

Re-directed T Cells for the Treatment (FAP)-Positive Malignant Pleural Mesothelioma

NCT01722149 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2019-08-07

No results posted yet for this study

Summary

MPM patients are not eligible for surgical procedures like decortication or pleuro-pneumectomy and have a median survival of 12 months with palliative chemotherapy. Therefore, new therapeutic approaches are of crucial need in this clinical situation. This is a phase I trial for patients with malignant pleural mesothelioma with pleural effusion testing the safety of a fixed single dose of 1x10e6 adoptively transferred FAP-specific re-directed T cells given directly in the pleural effusion. Lymphocytes will be taken 21 days before transfer from peripheral blood. CD8 positive T cells will be isolated and re-programmed by retroviral transfer of a chimeric antigen receptor (CAR) recognizing FAP which serves as target structure in MPM.

* Trial with immunomodulatory product / biological

Conditions

  • Malignant Pleural Mesothelioma

Interventions

GENETIC

Adoptive Transfer of re-directed T cells

Adoptive Transfer of 10e6 re-directed T cells in the pleural effusion

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Alessandra Curioni, MD · University Hospital Zurich, Division of Oncology

Study Design

Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-19
Primary Completion
2019-03-22
Completion
2019-07-18

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01722149 on ClinicalTrials.gov